We envisage that the RoseTTaFold method might allow the accurate prediction of FRA-1-containing multiprotein complexes and the design of potent and selective FRA-1 inhibitors [163], leading to the development of novel drugs for the inhibition of the FRA-1/AP-1-controlled transcriptional networks of EMT and metastasis in aggressive breast cancer. The gene discussed is JUN; the disease is breast cancer.